SZ-685C exhibits potent anticancer activity in both radiosensitive and radioresistant NPC cells through the miR-205-PTEN-Akt pathway

Wang,Dujuan; Wang,Sumei; Liu,Qin; Wang,Mengyao; Wang,Chunhua; Yang,Huiling

doi:10.3892/or.2013.2376

SZ-685C exhibits potent anticancer activity in both radiosensitive and radioresistant NPC cells through the miR-205-PTEN-Akt pathway

Authors:
- Dujuan Wang
- Sumei Wang
- Qin Liu
- Mengyao Wang
- Chunhua Wang
- Huiling Yang
View Affiliations

Affiliations: Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong 510080, P.R. China
Published online on: April 3, 2013 https://doi.org/10.3892/or.2013.2376
Pages: 2341-2347

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radioresistance is a major obstacle to the treatment of human nasopharyngeal carcinoma (NPC). Emerging evidence has demonstrated that miRNAs are involved in cancer therapy resistance. Our research group established the radioresistant NPC cell line CNE2R derived from the CNE2 cell line, and demonstrated that irradiation-induced miR-205 determined the resistance of NPC through directly targeting PTEN. However, specific inhibitors targeting miRNAs are largely undetermined. SZ-685C was expected to abrogate the radioresistance of CNE2 cells through the miR-205‑PTEN-Akt pathway. SZ-685C exhibited a similar cytotoxic effect on both cell lines, and we demonstrated that both intrinsic and extrinsic pathways were activated by SZ-685C in the cell lines. Importantly, the miR-205-PTEN-Akt pathway was the key cell signaling pathway activated in the CNE2R cells upon SZ-685C treatment; however, the Stat3-Jab1-p27 pathway might participate in the pro-apoptotic effect in CNE2 cells but not in CNE2R cells. SZ-685C is a promising anticancer agent for treatment of NPC, and it exhibited pro-apoptotic activity in both radiosensitive and radioresistant NPC cells. Although the mechanisms between the two cell lines were not identical, the pro-apoptotic effects were similar between the two cell lines.

View Figures

View References

1	Her C: Nasopharyngeal cancer and the Southeast Asian patient. Am Fam Physician. 63:1776–1782. 2001.PubMed/NCBI
2	Lo KW, To KF and Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell. 5:423–428. 2004. View Article : Google Scholar : PubMed/NCBI
3	Qin L, Zhang X, Zhang L, et al: Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun. 371:531–535. 2008. View Article : Google Scholar : PubMed/NCBI
4	Schoof CR, Botelho EL, Izzotti A and dos Vasques LR: MicroRNAs in cancer treatment and prognosis. Am J Cancer Res. 2:414–433. 2012.PubMed/NCBI
5	Lee KM, Choi EJ and Kim IA: microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol. 101:171–176. 2011. View Article : Google Scholar : PubMed/NCBI
6	Jeong SH, Wu HG and Park WY: LIN28B confers radio-resistance through the posttranscriptional control of KRAS. Exp Mol Med. 41:912–918. 2009. View Article : Google Scholar : PubMed/NCBI
7	Tian W, Chen J, He H and Deng Y: MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. Clin Transl Oncol. Aug 23–2012.(Epub ahead of print).
8	Kanakkanthara A and Miller JH: MicroRNAs: novel mediators of resistance to microtubule-targeting agents. Cancer Treat Rev. 39:161–70. 2012. View Article : Google Scholar : PubMed/NCBI
9	Qu C, Liang Z, Huang J, et al: MiR-205 determines the radio-resistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle. 11:785–796. 2012. View Article : Google Scholar : PubMed/NCBI
10	She Z, Chen S, Lin Y, Yuan J, Pang J and Li M: SZ-685C preparation method and antitumor application. Application No: 00810028628.3, Application Date. 2008.6:6
11	Xie G, Zhu X, Li Q, et al: SZ-685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the Akt/FOXO pathway. Br J Pharmacol. 159:689–697. 2010. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Gan B, Liu D and Paik JH: FoxO family members in cancer. Cancer Biol Ther. 12:253–259. 2011. View Article : Google Scholar : PubMed/NCBI
13	Zhu X, He Z, Wu J, et al: A marine anthraquinone SZ-685C overrides adriamycin-resistance in breast cancer cells through suppressing Akt signaling. Mar Drugs. 10:694–711. 2012. View Article : Google Scholar : PubMed/NCBI
14	Hitomi J, Katayama T, Eguchi Y, et al: Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. J Cell Biol. 165:347–356. 2004. View Article : Google Scholar : PubMed/NCBI
15	Tadros SF, D’Souza M, Zhu X and Frisina RD: Apoptosis-related genes change their expression with age and hearing loss in the mouse cochlea. Apoptosis. 13:1303–1321. 2008. View Article : Google Scholar : PubMed/NCBI
16	LoPiccolo J, Granville CA, Gills JJ and Dennis PA: Targeting Akt in cancer therapy. Anticancer Drugs. 18:861–874. 2007.
17	Eke I, Koch U, Hehlgans S, et al: PINCH1 regulates Akt1 activation and enhances radio-resistance by inhibiting PP1alpha. J Clin Invest. 120:2516–2527. 2010. View Article : Google Scholar : PubMed/NCBI
18	Song MS, Salmena L and Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 13:283–296. 2012.PubMed/NCBI
19	Li SS, Yang S, Wang S, Yang XM, Tang QL and Wang SH: Latent membrane protein 1 mediates the resistance of nasopharyngeal carcinoma cells to TRAIL-induced apoptosis by activation of the PI3K/Akt signaling pathway. Oncol Rep. 26:1573–1579. 2011.PubMed/NCBI
20	Kraus AC, Ferber I, Bachmann SO, et al: In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene. 21:8683–8695. 2002. View Article : Google Scholar : PubMed/NCBI
21	Tomoda K, Kubota Y and Kato J: Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature. 398:160–165. 1999. View Article : Google Scholar : PubMed/NCBI
22	Oh W, Lee EW, Sung YH, et al: Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. J Biol Chem. 281:17457–17465. 2006. View Article : Google Scholar : PubMed/NCBI
23	Wan M, Cao X, Wu Y, et al: Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation. EMBO Rep. 3:171–176. 2002. View Article : Google Scholar : PubMed/NCBI
24	Pan Y, Zhang Q, Tian L, et al: Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Res. 72:1890–1900. 2012. View Article : Google Scholar : PubMed/NCBI
25	Shackleford TJ, Zhang Q, Tian L, et al: Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells. Breast Cancer Res. 13:R652011. View Article : Google Scholar : PubMed/NCBI
26	Zhang J, Chen F, Li W, et al: 14-3-3ζ interacts with stat3 and regulates its constitutive activation in multiple myeloma cells. PLoS One. 7:e295542012.
27	Azijli K, Yuvaraj S, Peppelenbosch MP, et al: Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3 dependent invasion in resistant non-small cell lung cancer cells. J Cell Sci. 125:4651–4661. 2012. View Article : Google Scholar : PubMed/NCBI
28	Chen F: JNK dependent Stat3 phosphorylation contributes to Akt activation in response to arsenic exposure. Toxicol Sci. 129:363–371. 2012. View Article : Google Scholar : PubMed/NCBI